Amino acid replacement: P298S.
C19764305T
P221S | GluClalpha-PE; P299S | GluClalpha-PF; P299S | GluClalpha-PH; P299S | GluClalpha-PI; P300S | GluClalpha-PJ; P299S | GluClalpha-PK; P300S | GluClalpha-PL; P299S | GluClalpha-PM; P299S | GluClalpha-PN; P299S | GluClalpha-PO; P299S | GluClalpha-PP
P298S
The reference strain has a Pro at residue 298 (TCG). This change is associated with drug resistance and reduced mobility relative to a strain with a Ser residue at this location.
GluClαglc1/Df(3R)BSC809 is a suppressor of abnormal neurophysiology | larval stage phenotype of Scer\GAL4VGlut1-OK371, VGlut1UAS.cDa
GluClαglc1/GluClalpha[+] is a non-suppressor of abnormal neurophysiology | larval stage phenotype of Eaat1hypo
GluClαglc1/GluClalpha[+] is a non-suppressor of abnormal locomotor behavior | larval stage phenotype of Eaat1hypo
GluClαglc1/Df(3R)BSC809 is a suppressor of embryonic/larval neuromuscular junction phenotype of Scer\GAL4VGlut1-OK371, VGlut1UAS.cDa
GluClαglc1/Df(3R)BSC809 is a suppressor of muscle cell of A1-7 ventral longitudinal muscle 3 | larval stage phenotype of Scer\GAL4VGlut1-OK371, VGlut1UAS.cDa
GluClαglc1/GluClalpha[+] is a non-suppressor of embryonic/larval neuromuscular junction | larval stage phenotype of Eaat1hypo